SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

24 marketing jobs

Bristol Myers Squibb logo
5 months ago

Senior Manager, Marketing Operations

Bristol Myers Squibb

Princeton, NJ (Hybrid)Full time$123K/yr – $149K/yr
Bristol Myers Squibb logo
5 months ago

Vice President, U.S. Brand Lead, KarXT, Alzheimer's Disease Psychosis

Bristol Myers Squibb

Princeton, NJ (On-site)Full time$296K/yr – $358K/yr
Bristol Myers Squibb logo
5 months ago

Associate Director U.S., HCP Marketing Admilparant (PPF)

Bristol Myers Squibb

Princeton, NJ (Hybrid)Full time$165K/yr – $200K/yr
Bristol Myers Squibb logo
5 months ago

Director, CAMZYOS Brand Strategy and Commercial Effectiveness

Bristol Myers Squibb

Princeton, NJ (Hybrid)Full time$202K/yr – $245K/yr
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

24 jobs
Bristol Myers Squibb logo

Senior Manager, Marketing Operations

Bristol Myers Squibb

Princeton, NJ (Hybrid)

$123K/yr - $149K/yrIn-houseFull-timeSenior level3+ years exp.
5 months ago
Bristol Myers Squibb logo

Vice President, U.S. Brand Lead, KarXT, Alzheimer's Disease Psychosis

Bristol Myers Squibb

Princeton, NJ (On-site)

$296K/yr - $358K/yrIn-houseFull-timeSenior level15+ years exp.
5 months ago
Bristol Myers Squibb logo

Associate Director U.S., HCP Marketing Admilparant (PPF)

Bristol Myers Squibb

Princeton, NJ (Hybrid)

$165K/yr - $200K/yrIn-houseFull-timeSenior level5+ years exp.
5 months ago
Bristol Myers Squibb logo

Director, CAMZYOS Brand Strategy and Commercial Effectiveness

Bristol Myers Squibb

Princeton, NJ (Hybrid)

$202K/yr - $245K/yrIn-houseFull-timeSenior level8+ years exp.
5 months ago
Previous12
Bristol Myers Squibb logo
Bristol Myers Squibb

Senior Manager, Marketing Operations

Princeton, NJ (Hybrid)

$123K/yr – $149K/yrSenior Level3+ years expFull time

Posted 5 months ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Drive regulatory-compliant content operations and launch readiness for pharma products with cross-functional collaboration and data-informed decision making.

  • Must-have: Proficiency with Veeva PromoMats and regulatory workflows.
  • Standout: Leads launch milestones and end-to-end Promotional Review processes (PReP).

Job Description

Responsibilities

  • Strategic Judgment, Insight & Continuous Improvement - Understand the spirit and intent of policies and processes by exercising sound judgment and structured decision‑making to navigate ambiguity, manage risk, and keep work moving forward without unnecessary escalation.
  • Demonstrate critical, creative thinking and problem-solving skills; produce clear, concise, and persuasive written and verbal communications; and enhance stakeholder communications with insights and actionable recommendations.
  • Provide solutions and contingency plans to facilitate business success; exerts appropriate authority for process exceptions; holds self‑accountable for results; and brings innovative approaches to project challenges.
  • Use data, metrics, and insights to inform decisions, proactively solve problems, and improve operational outcomes.
  • Drive continuous improvement by simplifying processes, enhancing ways of working, and sharing best practices and lessons learned across teams.

Requirements

  • Bachelor’s degree or equivalent required; graduate degree a plus.
  • 3+ years of experience in the pharmaceutical industry with demonstrated understanding of promotional review processes and compliance-regulated environments.
  • Strong proficiency in Veeva PromoMats and familiarity with AI-enabled tools in marketing or compliance workflows.
  • Proven ability to manage complex processes, tight timelines, and cross-functional stakeholders.
  • Experience partnering effectively with Marketing, Medical, Regulatory, and Legal teams.
  • Strong facilitation, communication, and presentation skills with a focus on driving clear decisions and outcomes.
  • Agile, continuous-improvement mindset with the ability to balance strategic thinking and hands-on execution.

Preferred

  • Graduate degree is a plus.

Benefits

  • Health Coverage: Medical, pharmacy, dental, and vision care.
  • Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP).
  • Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support.
  • Work-life benefits include: Paid Time Off
  • US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
  • Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays
  • Based on eligibility*, additional time off for employees may include unlimited paid sick time, up to 2 paid volunteer days per year, summer hours flexibility, leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs and an annual Global Shutdown between Christmas and New Years Day.
Bristol Myers Squibb logo

Bristol Myers Squibb

3.7 Glassdoor

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Lawrence, New Jersey, USA
38K employees (1,574 in marketing)
www.bms.com
69% recommend to a friend
70% CEO approval

Salaries

Posted range

$123K/yr – $149K/yr

Taken straight from the job posting.

See all Bristol Myers Squibb salaries

Marketing Team

Marketing Team Size
1,254 (3% of company)
Median Career Experience
19 years
Median Tenure
6.2 years
Marketing Roles Posted (Last 30 Days)
8

People

HR / Recruitment

RoseMary Costa-Lopes
RoseMary Costa-Lopes
Director, Talent Acquisition Marketing Strategy and Delivery
At the company for 6 years 2 months
Amanda Mioli
Amanda Mioli
Senior Manager, Content Strategist & Recruitment Marketing
At the company for 11 months

Marketing Leadership

Filip Odqvist
Filip Odqvist
Vice President CELMoDs, US Oncology Marketing
At the company for 13 years 3 months
Patricia Yap
Patricia Yap
Vice President of Marketing - SOTYKTU
At the company for 25 years 7 months
Patricia Russo
Patricia Russo
Vice President US Marketing, Neuroscience
At the company for 2 years 11 months
Rindy Dhillon
Rindy Dhillon
Vice President, US Oncology Lung and GI Marketing
At the company for 4 years 5 months

Funding

Total Funding
$29.3B
Last Raise
$5.7B
Post IPO Debt, 4 months ago

Funding History

  • Nov 2025
    Post IPO Debt • $5.7B
  • Feb 2024
    Post IPO Debt • $13B
  • Oct 2023
    Post IPO Debt • $4.5B

Traffic Signals

Monthly Visitors
966.3K
Monthly Google Ads Budget
$2.4K
Traffic Source Mix
Search
38.1%
Direct
48.6%
Referral
9%
Social
3.3%
Paid
1%

Headcount Trend

Current headcount: ~38.3K

Recent News

Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan
Dec 5, 2025 • Fortune
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Dec 5, 2025 • Bristol Myers Squibb
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
Dec 3, 2025 • MarketWatch
With site 'irregularities,' Bristol Myers delays key Cobenfy readout in Alzheimer's psychosis
Dec 3, 2025 • Fierce Pharma
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
Dec 1, 2025 • Reuters
A Fresh Look at Bristol-Myers Squibb (BMY) Valuation After Recent Share Price Rebound
Nov 25, 2025 • Yahoo Finance
Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?
Nov 23, 2025 • Yahoo Finance
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance (NYSE:BMY)
Nov 21, 2025 • Seeking Alpha
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness
Nov 20, 2025 • Reuters
Merck, Bristol Myers Squibb plan NJ layoffs (updated)
Nov 20, 2025 • NJBIZ
Buy Bristol Myers Squibb Stock. The Drugmaker Is Too Cheap to Ignore.
Nov 20, 2025 • Barron's
Bristol Myers Shares Sink on Yet Another Trial Failure
Nov 14, 2025 • Barron's
Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial
Nov 14, 2025 • statnews.com
Bristol-Myers Squibb (BMY): Assessing Valuation After Improved Profits and Upgraded Revenue Guidance
Nov 11, 2025 • Yahoo Finance
Bristol Myers Squibb CDTO Greg Meyers on biopharma’s AI-enabled future
Nov 6, 2025 • McKinsey & Company
Bristol-Myers Squibb's (NYSE:BMY) Earnings May Just Be The Starting Point
Nov 6, 2025 • Yahoo Finance
Bristol Myers reaches $239 million settlement over psoriasis, MS drugs
Nov 5, 2025 • Reuters
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
Nov 3, 2025 • Yahoo Finance
Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why
Oct 30, 2025 • Yahoo Finance
Bristol Myers beats quarterly revenue estimates on strong Opdivo sales
Oct 30, 2025 • Reuters
Bristol Myers Squibb Profit Soars, Raises Revenue Guidance
Oct 30, 2025 • The Wall Street Journal
A Fresh Look at Bristol-Myers Squibb's Valuation After New Pipeline Progress and Phase 3 Sotyktu Results
Oct 28, 2025 • Yahoo Finance
Bristol-Myers Squibb: Earnings Champion Valued Like A Loser (NYSE:BMY)
Oct 27, 2025 • Seeking Alpha
Bristol-Myers Squibb Stock Forecast: Where Analysts See the Stock Going by 2027
Oct 25, 2025 • TIKR.com
Bristol-Myers Squibb: This High FCF Yield Is The Best Value In Healthcare
Oct 23, 2025 • Seeking Alpha
Does Bristol-Myers Squibb’s 22% Drop in 2024 Suggest an Opportunity for Investors?
Oct 23, 2025 • Yahoo Finance
The Play On Bristol-Myers Squibb (NYSE:BMY)
Oct 21, 2025 • Seeking Alpha
Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know
Oct 21, 2025 • Yahoo Finance
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn
Oct 14, 2025 • European Pharmaceutical Review
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend
Oct 13, 2025 • Yahoo Finance
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
Oct 13, 2025 • PR Newswire
Bristol-Myers Squibb (BMY): Assessing Valuation as Shares Slide Nearly 5% Over the Past Month
Oct 12, 2025 • Yahoo Finance
Bristol Myers Squibb: Value Emerges From Distress
Oct 11, 2025 • Seeking Alpha
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push
Oct 10, 2025 • Reuters
Bristol Myers to buy startup Orbital Therapeutics, building out cell therapy pipeline
Oct 10, 2025 • statnews.com
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Oct 10, 2025 • Yahoo Finance
Bristol Myers Squibb to buy RNA start-up for $1.5 billion
Oct 10, 2025 • Chemical & Engineering News
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
Oct 10, 2025 • Pharmaceutical Executive
Bristol Myers Squibb to acquire Orbital for $1.5B
Oct 10, 2025 • NJBIZ
Bristol Myers Squibb Moves Into In Vivo CAR T with $1.5 Billion Orbital Buy
Oct 10, 2025 • Inside Precision Medicine
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Oct 8, 2025 • Yahoo Finance
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
Oct 7, 2025 • Yahoo Finance
Investing Smart: Bristol-Myers Squibb (BMY) Among the Best Affordable Dividend Stocks
Oct 5, 2025 • Yahoo Finance
Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery
Oct 3, 2025 • Yahoo Finance
PRT Case Against Bristol-Myers Squibb to Proceed
Oct 2, 2025 • planadviser
Bristol Myers, Takeda to pool data for AI-based drug discovery
Oct 1, 2025 • Reuters
Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today
Oct 1, 2025 • Yahoo Finance
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
Sep 30, 2025 • Yahoo Finance
How Bristol-Myers Squibb Company (BMY) Delivers Strong Yields Even in Tough Markets
Sep 29, 2025 • Yahoo Finance
Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship
Sep 29, 2025 • BioSpace
6 FDA Decisions to Watch For in Q4
Sep 29, 2025 • BioSpace
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Sep 29, 2025 • Revolution Medicines, Inc.
Everbridge to Showcase AI‑Powered High Velocity CEM at GSX 2025
Sep 29, 2025 • Morningstar.com
United States Cancer Therapeutics Market to Hit $491.6 Billion by 2032, Driven by Precision and Immunotherapy Advances
Sep 29, 2025 • EIN Presswire
A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative
Sep 28, 2025 • Yahoo Finance
Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios
Sep 27, 2025 • Yahoo Finance
STAT+: Days before Trump deadline to lower prices, companies push a flurry of initiatives. Will it be enough?
Sep 26, 2025 • STAT
Trump’s drug tariffs are days away. Massachusetts’ pharma companies aren’t worried.
Sep 26, 2025 • Boston Globe
BMS adds discounted psoriasis drug to its DTC channel
Sep 26, 2025 • pharmaphorum
Anemia Treatment Market Analysis by Disease Type, Therapy Class, Route of Administration, Countries and Competitive Landscape 2025-2033
Sep 26, 2025 • Research and Markets
Trump to put tariffs on heavy trucks, citing need to protect Mack Trucks, other US manufacturers from ‘unfair outside competition’
Sep 26, 2025 • The Morning Call
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
Sep 26, 2025 • MarketScreener
Bristol Myers Squibb leans into direct-to-consumer with telehealth launch, drug price drop
Sep 25, 2025 • eMarketer
Bristol Myers to sell psoriasis drug at over 80% discount to some US patients
Sep 25, 2025 • Reuters
BMS plots another DTC platform, this one offering Sotyktu at 86% discount to cash-pay patients
Sep 25, 2025 • Fierce Pharma
Bristol Myers Squibb to Offer More Than 80% off Sotyktu List Price
Sep 25, 2025 • Managed Healthcare Executive
Immunology Drug Sotyktu Will Kick Off Bristol Myers Squibb’s New Direct-to-Patient Platform
Sep 25, 2025 • MedCity News
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
Sep 24, 2025 • Yahoo Finance
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
Sep 24, 2025 • PR Newswire
BMS Phase III success with iberdomide
Sep 24, 2025 • Pharma Letter
BMS eyes filings for myeloma 'celmod' iberdomide
Sep 24, 2025 • pharmaphorum
Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment
Sep 23, 2025 • Yahoo Finance
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients
Sep 23, 2025 • Benzinga.com
Confidence on Hold Until Powell Weighs In
Sep 23, 2025 • MarketScreener
Transcript : Bristol-Myers Squibb Company Presents at Bernstein Insights
Sep 23, 2025 • MarketScreener
Bristol Myers' iberdomide shows improvement in Phase 3 myeloma study
Sep 23, 2025 • thefly.com
Bristol Myers to launch Cobenfy in UK at a list price equal to the USA
Sep 23, 2025 • Pharma Letter
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US list price
Sep 23, 2025 • PharmiWeb
New Subcutaneous Formulation of OPDIVO® Receives Positive INESSS Recommendation for Multiple Tumour Types Français
Sep 23, 2025 • Canada NewsWire
New Subcutaneous Formulation of OPDIVO® Receives Positive INESSS Recommendation for Multiple Tumour Types
Sep 23, 2025 • BioSpace
Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma
Sep 23, 2025 • FierceBiotech
Bristol Myers Squibb Commits to Veeva Vault CRM
Sep 22, 2025 • Yahoo Finance
In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy
Sep 22, 2025 • Fierce Pharma
Bristol Myers plans UK launch of schizophrenia drug Cobenfy, matching US price
Sep 22, 2025 • Reuters
Bristol Myers Squibb Commits to Veeva Vault CRM
Sep 22, 2025 • PR Newswire UK
Fortrea Appoints William Sharbaugh to Board of Directors
Sep 22, 2025 • Fortrea Holdings Inc
Bristol Myers plans UK launch of schizophrenia drug in 2026
Sep 22, 2025 • MarketScreener
Psychedelics Space Enters New Era as AbbVie Dives In
Sep 22, 2025 • BioSpace
Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight
Sep 22, 2025 • DelveInsight Business Research LLP
Veeva says Bristol Myers commits to Veeva Vault CRM
Sep 22, 2025 • thefly.com
FDA clears subcutaneous Keytruda in a boost to MSD
Sep 22, 2025 • pharmaphorum
UK under pressure as BMS sets US-level price for schizophrenia drug
Sep 22, 2025 • Companies
Fortrea Appoints William Sharbaugh to Board of Directors
Sep 22, 2025 • citybiz
Wall Street: Resilience or Denial?
Sep 22, 2025 • MarketScreener
Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval
Sep 21, 2025 • MedCity News
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
Sep 19, 2025 • Yahoo Finance
Liver Cancer Therapeutics Market Size Surpasses USD 13.16 Billion by 2032, Increasing at a CAGR of 16.5% from 2025 to 2033
Sep 19, 2025 • PR Newswire
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
Sep 19, 2025 • Morningstar.com
Replimune lacks clear pathway in melanoma after FDA meeting
Sep 19, 2025 • Pharma Letter
Fierce Pharma Asia—BMS’ China asset sale; 2 biotech debuts; 2 potential deals
Sep 19, 2025 • FiercePharma

Links

www.bms.comLinkedInX (Twitter)Crunchbase